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Abstract
The understanding of complex physical or biological systems nearly always re-
quires a characterisation of the variability that underpins these processes. In ad-
dition, the data used to calibrate such models may also often exhibit considerable
variability. A recent approach to deal with these issues has been to calibrate pop-
ulations of models (POMs), that is multiple copies of a single mathematical model
but with different parameter values. To date this calibration has been limited to
selecting models that produce outputs that fall within the ranges of the dataset,
ignoring any trends that might be present in the data. We present here a novel and
general methodology for calibrating POMs to the distributions of a set of measured
values in a dataset. We demonstrate the benefits of our technique using a dataset
from a cardiac atrial electrophysiology study based on the differences in atrial ac-
tion potential readings between patients exhibiting sinus rhythm (SR) or chronic
atrial fibrillation (cAF) and the Courtemanche-Ramirez-Nattel model for human
atrial action potentials. Our approach accurately captures the variability inherent
in the experimental population, and allows us to identify the differences underlying
stratified data as well as the effects of drug block.
Introduction
Mathematical modelling is vital for the understanding of complex phenomena, but the use
of mathematical models requires careful specification of their parameter values against
available data. In many applications, model predictions can vary sharply in response
to even small changes in the values of their parameters, and yet experimental efforts to
determine these values are invariably associated with either some kind of uncertainty
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or inherent variability underlying the processes that are being measured. In biological
and physiological contexts, for example, not only are these uncertainties typically very
large, the values of representative parameters also exhibit considerable variation between
different members of a population, due to differences in physiology and genetics. Prop-
erly accounting for this variability using mathematical models is critical to furthering
understanding in such fields [1].
With regards to uncertainty quantification (UQ), techniques such as Monte Carlo
sampling [2], polynomial chaos expansions [3], and Bayesian approaches including Gaus-
sian processes [4], allow for the impacts of uncertainty in parameter values upon model
outputs (predictions) to be quantified, or for parameter values and their uncertainties
to be determined in response to data collected for model outputs. However, each works
from the perspective of a single, immutable model with some fixed uncertainties in its
inputs and corresponding uncertainties in its outputs. This becomes an issue when one
wishes for example to determine which features (parameter values) in a population pre-
dict different classes of outputs, or to consider the impacts of changes to the underlying
model itself.
On the other hand, a very natural approach for modelling and understanding the
variability within populations is the recent technique known as populations of models
(POMs) [5, 6, 7]. In this approach, a collection of varying individuals is represented in
kind by a collection of individual models, with the idea that the collection of models
exhibits the same variability as the population being modelled. Although each individual
model typically differs only in terms of the values of its parameters, each remains a
model in its own right, allowing for subpopulations within the POM to be identified
and analysed, and for the underlying model to be easily adjusted once a POM has been
constructed. Somewhat related are genetic algorithms that use multiple copies of a model
with differing parameter values as their organisms [8], although there the focus is on
breeding a single model that best fits data for a single individual, and not on characterising
variability in a population.
Candidate models for a population can be generated simply by randomly sampling
from a reasonable parameter space, but of course care should be taken to ensure that
the models which compose the POM are physically (or physiologically) realistic. This
is typically achieved by comparing the outputs of these candidate models to available
experimental data, a process known as calibration of POMs [9]. In the sphere of cardiac
electrophysiology, where POMs research has been very active, calibrated POMs have
been used to great effect. This includes suggesting modifications to existing models of
rabbit ventricular cells [10] and human atrial cells [11] required to reproduce specific data,
determining the electrophysiological properties that lead to the dangerous phenomena of
alternans [12, 13] and atrial fibrillation [14], and characterising the sources of the differing
function of failing hearts [15]. The technique has also been used to explore the variable
response of a population to drug-induced potassium channel block [7, 16], to the onset
of ischemia in rabbits [17], and the effects of hypertrophic cardiomyopathy [18]. Most
relevant to our work, calibrated POMs were used by Sanchez et al. [19] to explore the
differences between patients exhibiting sinus rhythm (SR) or chronic atrial fibrillation
(cAF), including identification of the impacts of cAF-induced remodelling by considering
the differences in channel conductances between the POMs calibrated to the healthy and
pathological datasets.
To date, calibration of POMs has been achieved almost exclusively by rejecting any
trialled models that produce outputs that correspond to measurable quantities falling
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outside the ranges of observations for those same quantities in the dataset [9]. This
prevents any obviously unphysical models from being accepted into the population, but
does not necessarily guarantee that the resulting POM directly corresponds to the data.
Selection of models according to the ranges of values observed in the data creates a
feasible region that is necessarily hyperrectangular, whereas the actual multidimensional
spread of experimental measurements may be a much more complex shape. Additionally,
it may be desirable that the selected models are not only feasible, but also that together
they exhibit the same features as seen in the data (such as regions of high or low density,
and correlations between measured quantities). One recent work did calibrate a POM by
ensuring that the models together exhibited appropriate mean and standard deviation
for the output variable of interest [20], a step towards the distribution-driven calibration
technique we introduce in this publication.
In this work, we extend a recent statistically-informed sampling technique for POM
construction [16] in order to propose a new method that produces POMs that are directly
calibrated to data distributions. A consequence of this process is that it ensures that se-
lected models lie in data-dense regions of the space of observables wherever possible. We
demonstrate our technique using the data of Sanchez et al., taken from patients exhibit-
ing either healthy SR of cAF. This allows us to show not only how our calibrated POMs
serve as accurate in silico representations of variable populations, but also how capturing
specific features in data illuminates the differences between stratified populations includ-
ing electrophysiological features that underpin the cAF pathology, as well as variable
responses to drug block treatment. We finally conclude by discussing our new approach,
when and how it should be used, and the implications for modelling and understanding
variability in all its manifestations.
Results
SMC Significantly Improves Calibration of Populations of Mod-
els to Data
The action of the heart depends on the excitable, highly nonlinear [21] nature of cardiac
cells, which undergo a carefully-controlled process of ion uptake and release in response
to electrical stimulus. In addition to the temporary intake of Ca2+ ions that produces
the cellular contraction associated with the heartbeat, control of the potential difference
across the cell’s membrane also prevents it from being re-stimulated too quickly. The
change in membrane potential in response to stimulus is known as the action potential
(AP), and it is commonly recorded in single-cell experiments.
The Sanchez et al. data quantifies APs recorded from the right atrial appendages of
patients exhibiting either healthy SR or cAF in terms of their biomarkers, measures of
key AP properties that together define the important features of the AP’s shape. These
biomarkers are the action potential duration (APD), action potential amplitude (APA),
resting membrane potential (RMP), maximum upstroke velocity (dV
dt max
) and potential
at 20% repolarisation (V20), with more information regarding the biomarkers provided in
Materials and Methods. The biomarkers are the output variables of the model in our case,
and so our goal is to construct populations of AP models that produce values of these
biomarkers that exhibit the same variability as that seen in the experimentally recorded
values. We use our sequential Monte Carlo (SMC) algorithm (detailed in Materials
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and Methods) to select models that, when taken together as a population, possess this
property, and compare these to the POMs generated using Latin hypercube sampling
(LHS) [22] matched to the ranges of the data, the typical approach for the construction
of calibrated POMs [9]. We note that the SMC approach laid out by Drovandi et al.
[16] could also be used to generate samples matched to biomarker ranges. Range-based
calibration is highly appropriate in the case of a low number of experimental recordings,
where there is insufficient information to derive an approximate distribution for the data.
POMs were constructed using the Courtemanche–Ramirez–Nattel (CRN) model [23]
for atrial APs, with the conductance of all its currents important to the AP (eleven in
total, including intracellular Ca2+ uptake and release) allowed to vary by ±100% of the
values originally published. Selection of a wide parameter space allows us to successfully
find parameter values appropriate for the data against which we calibrate, though we also
explore later the effects and implications of our calibration processes when we vary pa-
rameters by a smaller extent. Further information and justification regarding the choice
of AP model and the currents that are varied is provided in Materials and Methods.
Initialising the SMC algorithm with 2000 particles, we obtained POMs composed of 1938
unique models for the SR data (those exhibiting sinus rhythm), and 1931 unique models
for the cAF data (those exhibiting chronic atrial fibrillation). Using 10000 trialled models
generated using LHS (10 samples with 1000 divisions in each parameter dimension) pro-
duced 1319 accepted models for the SR dataset and 1338 models for the cAF dataset. We
note that these numbers should not be compared as a measure of efficiency, for the SMC
algorithm involves multiple model runs for each particle and is solving a more difficult
sampling problem that takes the distributions of the data into account.
For the SR dataset the SMC-calibrated POMs show a significantly better degree
of localisation to data-dense regions in the biomarker space, when compared to POMs
calibrated to biomarker ranges (Figure 1). The effects of bias inherent to the underlying
model are greatly reduced, as best demonstrated by the biomarkers APD90, RMP and
APA. Over the selected range of parameters, the CRN model tends to produce APD90
values lower than the majority of the data, and APA values higher than the majority of
the data, and when matching to ranges there is nothing to prevent these models from
being over-represented in the final population. The SMC-constructed population captures
very well the extent of variance in the V20 values in the dataset. However, bias is still
clearly present in RMP and dV
dt max
. Very similar results are seen for the cAF dataset (see
Figures S1 and S2).
It is clear that the CRN model cannot produce certain combinations of biomarker
values, regardless of the parameter values chosen within the search space, as can be seen
when different pairs of biomarkers are plotted (Figure 2). For example, the CRN model
demonstrates a very clear correlation between the maximum upstroke velocity and the
AP amplitude, a relationship that is not present in the data. We suggest this is not a
failing of the CRN model (indeed, it is expected that a faster upstroke will allow for
a higher peak membrane potential to be achieved while the cell’s ion channels adjust),
and thus the discrepancy between model and data likely arises due to the difficulties in
measuring the maximum upstroke velocity accurately in an experimental setting. We
also note that the POMs constructed here all use a single consistent stimulus protocol for
all members of the population, whereas experimental data collection is expected to show
some variation in applied stimulus current between cells, presenting another potential
source for this discrepancy. Nevertheless, the SMC algorithm successfully reduces the
impacts of model bias on POM construction, producing POMs that accurately reflect the
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Figure 1: Calibration to biomarker distributions as opposed to their ranges
reduces model bias. Marginal distributions of the biomarkers in the SR dataset (black)
and POMs calibrated to biomarker distributions using the SMC algorithm (blue) or
calibrated to biomarker ranges using LHS (red). The natural logarithm of APD20 values
is used to better display their distribution.
features of the data.
Refinement via Selection of Optimal Subpopulations Captures
Well the Variability in Datasets
When considering Figures 1 and 2, it is clear that there still remain some differences in
distribution between the models selected by the SMC algorithm and the data, particularly
in the case of the biomarker RMP. In order to address this issue, we include a second phase
of our calibration process that selectively removes models from the SMC-constructed
POMs in order to improve the correspondence between POM and data, which we term
“refinement”. The advantages of this refinement process in more closely matching the
data distributions is made clear in the results that follow.
Our easily-approximated divergence measure ρ provides a means for selecting this
subpopulation, using a simulated annealing-type algorithm (see Materials and Methods,
“Further POMs Refinement”). Of course, selecting a subpopulation from a POM can-
not produce coverage in areas of the biomarker space where the original POM has no
models, and so the aforementioned issues with the maximum upstroke velocity cannot be
addressed using our refinement technique. This motivates the use of a second divergence
measure ρˆ (see Materials and Methods) that reduces the emphasis on this biomarker. We
consider here the POMs formed by selecting subpopulations that minimise both measures.
For the SR dataset, minimising ρ produced a refined POM of 275 models with very
good representation of variability in the dataset (Figure 3), with the marginal distribu-
tions of the biomarkers matching very well apart from APD20, APA and
dV
dt max
. The
already observed coupling of APA and dV
dt max
makes it impossible to find models that
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Figure 2: Bivariate distributions of biomarker pairs are well captured by an
SMC-constructed POM. Pairwise scatterplots of each unique pair of biomarkers in
the SR dataset (white) and the POMs constructed using SMC matched to distributions
(blue) and LHS matched to ranges (red). The SMC-generated POM demonstrates good
localisation to the dense regions in the data, but clearly requires further calibration. An
obvious correlation between APA and dV
dt max
is exhibited by the model, regardless of the
sampling method used, but this correlation is not present in the data.
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Figure 3: Selection of an optimal subpopulation almost fully captures
biomarker variability. Marginal distributions of the biomarkers in the SR dataset
(black) and POMs selected as subpopulations of the SMC-generated POM that minimised
ρ (red) or ρˆ (blue). The simulated annealing algorithm clearly succeeds at selecting a
representative subpopulation, but the distributions of the APA and dV
dt
max are not quite
captured. Reducing the emphasis of dV
dt
max on the calibration process provides very good
capture of variability in all other biomarkers.
simultaneously capture the distributions of these two biomarkers, and we attempt to rec-
tify this using the modified divergence measure. By reducing the emphasis on dV
dt max
, the
refinement process is free to select models which at least capture the distribution of APA
values, the biomarker we expect to be more accurately measured.
When a subpopulation that minimises ρˆ is selected, the result is a POM composed
of 327 models that shows slight improvements in the marginal distributions of the other
biomarkers and a more significant improvement in APD20 (Figure 3). Most notably,
however, the distribution of APA values is now exceedingly well-represented in the POM,
as the algorithm’s efforts to minimise the divergence from the maximum upstroke velocity
no longer hamper its ability to fit the distribution of the highly correlated APA. This
improved performance also comes at little cost to the value of the unmodified divergence
measure ρ, as shown by Table 1, and so we favour POMs constructed by minimising ρˆ in
the remainder of this work.
Our refined POM captures the key statistical properties of each of the biomarkers
in the dataset very well, except for dV
dt max
which still suffers from the model’s general
underestimation of this value compared to the data ( Table 2). Figure 4 provides a visual
demonstration of the refinement process, showing the selection of a subpopulation of
models that corresponds well to the density of data across the biomarker space. Similarly
good performance is also achieved by refined POMs calibrated to the cAF dataset (Figures
S3 and S4 and Table S1), with again only dV
dt max
showing any significant deviation between
POM and data.
Our two-phase calibration technique is thus seen to be successful at producing POMs
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Population of Models SR data cAF data
ρ ρˆ ρ ρˆ
LHS, matched to ranges 2.76 2.41 2.74 2.42
SMC, matched to distributions 1.95 1.41 2.16 1.74
SMC subpopulation, minimising ρ 1.36 0.68 1.21 0.70
SMC subpopulation, minimising ρˆ 1.47 0.49 1.28 0.57
Table 1: SMC produces more representative POMs than LHS matched to
ranges for both datasets, and overall performance after subsequent refinement
is similar in both cases. Comparison of the ability of different POMs to capture
the between-subject variability in two clinical datasets, as provided by the divergence
measures ρ and ρˆ. Lower ρ values indicate a better fit to the distributions, demonstrating
a significant gain from both the SMC and from choosing an optimal subpopulation. For
reference, a complete divergence between data and POM would produce ρmax = 5.83 and
ρˆmax = 5.00.
that accurately reflect the data, at least to the extent that the underlying model can
over the specified parameter space. Here this has been achieved for multiple datasets
that show significant variation between individual samples, using a strongly nonlinear
model and a moderately high number of variable parameters. Although the selection
of optimal subpopulations did require the rejection of a large proportion of the models
selected by the SMC algorithm in this case (∼83% for the SR dataset), larger POMs can
be generated as desired by using additional particles in the original SMC algorithm, or
by modifying the ‘energy’ minimised in the refinement process so that POMs of a larger
size are encouraged.
Distributional Calibration Produces Populations of Models that
Capture Important Data Features
The POMs constructed for the SR and cAF dataset using our calibration technique cap-
ture very well the features of the data, but a natural question is whether this calibration
actually produces quantifiable differences in the models that are selected, and their out-
puts. Here, the most critical output of the population of CRN models are the APs, shown
in Figure 5. Significant differences between the SR and cAF populations are immediately
observed. SR APs demonstrate an initial period of very rapid repolarisation after the
AP peak, then an extended plateau phase that eventually resumes gradual repolarisation
back to the resting potential. In contrast, cAF APs show much less significant initial repo-
larisation, but their lack of any significant plateau phase and overall faster repolarisation
produces significantly lower APDs (and hence a decreased refractory period).
These features are well known to be associated with cAF, which is characterised by
far more triangular APs that lack a noticeable plateau phase and return to resting poten-
tial more rapidly than APs in healthy sinus rhythm [24]. The morphological differences
between SR and cAF APs are seen in the data, with the rapid repolarisation followed by
plateau in the SR population implied by very small APD20 values and larger APD50 val-
ues, while the AP triangulation in the cAF population is seen in larger APD20 but smaller
APD50 values. Calibrating to distributions naturally takes these features of the data into
account, successfully selecting models that predict the appropriate morphologies. When
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Figure 4: Simulated annealing successfully selects models according to data
density in the biomarker space. Pairwise scatterplots of each unique pair of biomark-
ers in the SR dataset (white) and the models from the SMC-generated POM that were
accepted (light blue) or rejected (dark red) in the process of minimising ρˆ. Outside of
dV
dt max
, the features of the data are very well represented by the final POM.
Figure 5: Distributional calibration captures the morphological differences be-
tween SR and cAF atrial action potentials. Atrial action potentials produced by
simulation of the populations of CRN models calibrated to biomarker data for patients
exhibiting sinus rhythm (blue) and chronic atrial fibrillation (red). Also displayed are
the average of all traces for the sinus rhythm (solid) and atrial fibrillation (dashed) pop-
ulations. The increase in AP triangulation and reduced refractory period associated with
chronic atrial fibrillation is clearly demonstrated, especially by the averaged traces.
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Biomarker Range Mean Std. Dev. JSD
APD90 (ms) 191−470 (193−467) 319 (318) 43 (44) 0.026
APD50 (ms) 7−215 (6−206) 142 (139) 40 (44) 0.066
APD20 (ms) 2−61 (2−63) 7 (7) 7 (8) 0.143
APA (mV) 77−120 (78−116) 95 (95) 7 (7) 0.021
RMP (mV) -87−-65 (-87−-61) -74 (-74) 4 (4) 0.059
V20 (mV) -37−6 (-39−11) -16 (-16) 6 (6) 0.041
dV
dt max
(V/s) 68−292 (48 −431) 156 (220) 34 (68) 0.426
Table 2: Summary statistics for the SR dataset are well recovered by the cali-
brated POM. Summary statistics for the POM calibrated to the distributions obtained
by minimising ρˆ in biomarkers exhibited by atrial cells in sinus rhythm, as compared to
the summary statistics for the experimental data itself (given in parentheses). Deviation
in the marginal distributions of each biomarker are specified in terms of the Jensen-
Shannon distance, calculated using equation (7). The statistical variation of the data is
seen to be well captured, apart from the maximum upstroke velocity, which also manifests
in a large JSD value.
calibrating to ranges for this dataset, the models selected do successfully produce APs
that show the reduced APD as associated with cAF, but are less successful in predicting
the accompanying differences in AP morphology (see Figure S5, also Figures 2 and 3
in [19]). We note that previous studies have created additional biomarkers that can be
expressed in terms of the original biomarkers, such as measures of triangulation based
on combinations of different APD values, in order to allow more effective calibration by
capturing these additional features — see [15]. Our method, however, does not depend
upon identifying the important trends in data or designing additional outputs to capture
them, making it generally applicable.
Accurate prediction of the specific shapes of the APs for SR and cAF patients is im-
portant as it suggests that the differential actions of the many ionic currents that together
produce the AP are being well captured by the POMs calibrated to distributions. This is
critical when it comes to using these POMs for further analysis, such as considering the
response of the different members of the population to drug treatments that act on spe-
cific cellular currents [7, 16], or identifying the differences in underlying electrophysiology
that characterises the two populations. We demonstrate these aspects in the following
subsection.
Distributional Calibration Produces POMs that Capture Key
Atrial Electrophysiological Aspects
(i) Impacts of cAF-induced Remodelling
We have constructed POMs calibrated to the SR and cAF datasets by varying the relative
strengths of the different currents that contribute to the human atrial AP, and thus any
significant differences in parameter values selected for the two datasets suggest that it is
changes in these currents that produce the modified APs associated with the cAF pathol-
ogy. Indeed, electrical remodelling of atrial myocytes that changes the densities of their
different ion channels is a well-known feature of cAF and contributes to the persistence of
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Figure 6: Accepted parameter values for the SR and cAF populations predict
well the changes in ionic behaviour associated with the cAF pathology. Boxplot
of θ values composing the POMs calibrated to the SR (blue) and cAF (red) datasets.
Values are expressed in relation to the base parameter values for the CRN model. Current
densities that show statistically significant differences (p < 0.001 from the Mann-Whitney
U test) are indicated with a *. The currents most well-known as remodelled in cAF (Ito,
IKur, IK1 and ICaL) all show significant differences in the correct directions.
the condition [25]. Dobrev and Ravens [26] provide a review of the experimental evidence
for the changes in current density associated with cAF, although further remodelling has
since been experimentally identified [27].
Sanchez et al. [19] also compared the POMs generated for the CRN model and the
models of Maleckar et al. [28] and Grandi et al. [29] when calibrated to the ranges of
the SR and the cAF data, by varing the six currents identified as most important to
AP properties. They identified a statistically significant upregulation of IK1 in all three
models, with changes in other currents found to be model-dependent. In the case of
the CRN model, Sanchez et al. also found statistically significant decreases in ICaL and
Ito in accordance with experimental observation [25]. However, the observed decreases
in Ito and ICaL were quite small and the POMs constructed failed to identify IKur as
a significantly downregulated current in cAF. Furthermore, INaCa showed a statistically
significant decrease, despite Na+/Ca2+ exchanger action being known to increase in cAF-
afflicted atria [30]. Our simulations using LHS calibrated to biomarker ranges also show
an erroneous decrease in INaCa and little to no change in ICaL and IKur, even with a
larger suite of currents now allowed to vary. In contrast, SMC-calibrated POMs show
significant differences in many current strengths between the SR and cAF populations
(Figure 6), and do very well at identifying the currents that are known to be remodelled
in response to cAF. We summarise the results in Table 3, comparing the experimentally
observed changes in current density to those predicted by our POMs calibrated to full
distributions or to only the ranges of the data.
In analysing Table 3 we see that the POMs calibrated to distributions underestimate
the extent of upregulation of IK1 and downregulation of ICaL, but identify that these
currents are, respectively, increased and decreased in cAF. The other critical current
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Parameter Exp. POMs POMs
(dist.) (ranges)
gNa l1 [31] +11% ↔
gto ∼ −70% [26] −85% −51%
gKur ∼ −50% [26] −40% −6%
gKr ↔2 [27] ↔ +10%
gKs ∼ +100% [32] ↔ ↔
gK1 ∼ +100% [26] +29% +33%
gCaL ∼ −70% [26, 33] −36% ↔
INaK(max) ↔ [34] ↔ +10%
INaCa(max) ∼ +40% [30] +41% −18%
Iup(max) l3 [35, 36] −39% ↔
krel ↑4 [35] ↔ ↔
Table 3: Experimentally observed changes in current density associated with
cAF are well predicted by POMs calibrated to distributions. Changes in median
current activities between the POMs calibrated to either the distributions, or the ranges
of the SR and cAF datasets, as compared with experimentally observed (Exp.) measure-
ments of changes in current densities associated with this pathology. Experimental figures
are taken from the specified references and rounded to the closest 10% to reflect the gen-
eral uncertainty in their measurements, and in some cases represent the combined result
of multiple studies. The ↔ symbol indicates no significant change observed (p ≥ 0.01
from the Mann-Whitney U test for POMs), and other symbols used are explained by the
following notes: 1Peak INa current is reduced, but sustained INa increased.
2Decreases in
mRNA levels have been observed [26], but no direct experimental evidence for IKr change
in cAF has yet been provided. 3Ca2+ uptake is reduced by decreased Serca2a levels, but
increased by enhanced phosphorylation of SERCA inhibitors. 4Ca2+ release is increased,
but in a ‘leaky’ fashion not necessarily best represented by changes to krel in the CRN
model. Distribution-calibrated POMs detect more of the differences in current densities
that underlie the cAF pathology, correlating well with experimentally-observed changes
in the greatest majority of current densities.
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changes associated with cAF are the reductions in Ito and IKur [25], that are also well
detected. We also predict the increase in INaCa activity that is expected. Although recent
experimental evidence suggests a strong upregulation of IKs in cAF [32], which has not
been observed here, this current has only a minor contribution to repolarisation in the
CRN model and this is likely the reason for a lack of any significant difference in the gKs
values selected for the two populations. The results here suggest that the net effect of
changes to atrial SERCA function (calcium uptake) is a decrease, as also used by Grandi
et al. to represent the cAF case in their AP model [29].
(ii) Response to Anti-arrhythmic Treatment
Arrhythmias in the heart are typically treated by drugs that block specific ion channels,
reducing the impact of the corresponding current(s) on the action potential. A common
target is the rapid component of the delayed K+ rectifier current (IKr), which activates
comparatively late in the AP and is a primary contributor to repolarisation in this phase.
Reducing flow due to this current hence prolongs the AP, and can restore SR in patients
with cAF [37]. IKr was also the current chosen to explore the differential response of a
variable population to drug treatment using POMs in a previous study [7].
In our POMs calibrated to the SR and cAF datasets, the cAF models show signifi-
cantly larger IKr that also activates slightly earlier (Figure 7a), contributing to the more
rapid repolarisation and lack of a plateau phase in the cAF APs. However, the maximum
conductance of the channel, gKr, shows no significant difference between the SR and cAF
POMs (see Table 3). This indicates that the increase in IKr activity is symptomatic of the
changed AP morphology in cAF, which impacts the voltage-dependent gating behaviour
of these ion channels.
We explore IKr block via drug treatment by first pacing the models in the cAF POM
until steady state (see Materials and Methods), then reducing gKr by 50% and repeat-
ing the full stimulus protocol. In correspondence with the observed effects of such drug
treatments, the APDs of almost all models (95%) are restored to values associated with
healthy SR (Figure 7b). This demonstrates the ability of our calibration to AP biomarker
measurements to produce models that exhibit appropriate behaviours even in situations
outside of those to which they were calibrated. However, there are a small number of mod-
els that predict decreased APD in response to treatment, as shown by the post-drugblock
APs (gold) that fall to the left of the untreated cAF APs (red), as well as a few models
that repolarise to unreaslitically high resting potentials (>−60mV). One advantage of the
POMs framework is that these models that show unexpected behaviour can be directly
examined in order to determine the underlying causes, potentially identifying risk factors
for these adverse reactions.
The models that repolarise extremely rapidly following treatment with IKr blocker are
seen to be associated with very small values of gNaK , and thus the unexpected behaviour
of these models likely stems from the selection of values for this parameter which are
too small to be physiologically realistic. This is a risk of choosing such a large (±100%)
extent of variation of our parameter values, further motivating our exploration of a lower
extent of variability in the following section. Nevertheless, these models do identify a
potential risk factor for the use of IKr-blocking treatments, namely that insufficient INaK
activity can result in dangerous further reduction of the refractory period. Examining
the current activity in these models reveals significant Na+ ion accumulation that occurs
due to the reduced action of INaK , which is further hampered by the reduced flow of K
+
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a)
b)
Figure 7: Calibration to distributions produces models that respond appropri-
ately to anti-arrhythmic treatment via IKr block. a) Traces of the rapid component
of the delayed rectifier K+ current for the models calibrated to the SR dataset (blue, solid)
and the cAF dataset (red, dashed). The cAF population demonstrates an almost twofold
increase in the activity of this current. b) APs after treatment by 50% IKr block (gold)
show significant AP prolongation compared to the same models without IKr block (red).
This is also demonstrated by the averaged traces for both (black lines, treated – solid,
untreated cAF – dashed). The restoration of atrial refractoriness in patients with cAF is
clearly demonstrated.
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ions through IKr. This then triggers extreme currents outward through the Na
+/Ca2+
exchanger, resulting in the extra-rapid repolarisation that is observed.
The models repolarising to resting potentials that are unrealistically high are seen
to be associated with incomplete deactivation of the L-type calcium channels and lower
values of gK1, resulting in an imbalance of inward and outward current in the unexcited
cell that gradually pushes up its membrane potential at rest. Eventually, an alternative
steady state is reached where the elevated resting potential largely prevents the cell’s
sodium channels from opening and the AP is severely disrupted. Parameter values that
lead to this behaviour will never be selected by the calibration process, because their APA
and RMP values fall outside of the data. However, when outward current due to IKr is
reduced by drug treatment and the balance of ion flow is changed, a few of the models
then fail to achieve correct homeostatic balance and instead end up at this alternative
steady state. The questions of whether other AP models also predict such alternative
steady states, and whether drug treatments can cause individual atrial cells to develop
disrupted balances of ion flow at rest (compensated for by their neighbours), are beyond
the scope of this paper.
The drugblock case study can thus be seen as a means of further calibrating the
generated POMs, by testing the ability of all of the models selected to continue predicting
reasonable AP curves when subject to established treatments. This is important given
the tendency for currents to compensate for one another, resulting in model behaviours
that only become manifest subject to this type of further interrogation. In the previous
study of Britton et al. [7], albeit using a different AP model, range-based calibration to
biomarkers recorded for different pacing frequencies was seen to be sufficient for avoiding
the selection of models that exhibit unphysical responses to drugblock.
(iii) Calibration of Model Parameters in Response to Variable Data
Although calibrated POMs are particularly suited to explaining variable data by creat-
ing representative populations, the technique can also be used to select a single set of
parameter values for a given model in response to available data. This is particularly
appropriate when variability in data is expected to source from uncertainty introduced
by the experimental process, or by other means not explained by model parameters.
Problems of this nature are inverse problems, and ubiquitous in a wide range of fields
[38]. Although numerous solution techniques for such problems exist, an advantage of
calibrated POMs in this context is that the space of parameter values that generate
outputs close to the data is provided as an output, similar to Bayesian approaches that
generate a posterior distribution for the parameters [38, 39]. Taking into account the
range of different parameter values that generate outputs close to the data, as opposed
to simply finding a set of parameters that generates an optimal output is important both
for supplying uncertainty estimates on parameter values and dealing with models where
disparate parameters can generate very similar outputs.
POMs calibrated successfully to data density represent a set of models that all cor-
respond in a sense to some portion of the data. Therefore, generating a single set of
parameter values from a distribution-calibrated POM is simply a matter of selecting an
appropriate means of condensing this set of models back into a single set of parameter
values. In our case, the set of parameter values selected for both the SR and cAF POMs
have a rather regular distribution (no obvious bimodal behaviour or obvious correlation
structures, see Figure S6), and so we take the median values of each individual parameter
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Figure 8: Selection of parameter values using distribution-calibrated POMs
produces updated models that correspond to provided data. SR (blue) and cAF
(red) APs, and the effects of 50% IKr block (gold) as predicted by the base CRN model
(dashed lines) and experimentally-calibrated CRN models using the median of POM θ
values (solid lines). The former predict significantly lower RMP and APD90 than sug-
gested by the data (mean values from the data for these biomarkers are indicated by
guidelines, SR – blue, cAF – red). The modified CRN models correctly predict RMP
and APD90 values that correspond to the data, and also successfully capture the antiar-
rhythmic effect of IKr block, demonstrating the restoration of an SR APD in the cAF
model.
to create two modified CRN models, one each for the SR and cAF datasets.
Figure 8 compares our modified CRN models to the baseline CRN model, and the
baseline CRN model modified for cAF using experimentally-informed adjustments to its
parameters taken from Table 3. It can immediately be seen that the original CRN model
for both SR and cAF underestimates the RMP and APD90, and that our modified CRN
models rectify this issue very well. More notably, the responses to drugblock treatment
predicted by the original and modified cAF models are completely different, with our
calibrated model demonstrating the correct restoration of APD to SR in response to IKr
block while the original CRN model demonstrates only very minor APD prolongation.
The original CRN model’s lack of response to IKr block is a result of the model’s prediction
of reduced IKr activity in cAF [40], in contradiction to the increase predicted by our POMs
(Figure 7a). Given the known efficacy of this type of treatment for the restoration of SR
in patients with cAF, we suggest that our technique of updating parameter values in
response to new experimental data using distribution-calibrated POMs can also produce
more predictive models in the case of for example drug treatments.
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Distributional Calibration Can Inform the Extent of Variability
in Parameter Values
Calibrating to distributions means that the variability in a supplied dataset can be ex-
pected to be explicitly captured by constructed POMs, so long as the model across the
specified parameter space is capable of generating outputs that match the data. This
means that by using divergence measures such as ρ and ρˆ, the differential ability of vari-
ous parameter spaces to capture variable data with POMs can be considered. The most
obvious application of this technique is to explore the level of variability in parameter
values needed to explain the data.
Our studies on the Sanchez et al. dataset have used a large variation in ion channel
conductance values (±100%), following previous studies [7, 19, 12]. Working with such
a variation in parameter values carries the risk of selecting extreme values that are not
physiologically sound (for example values close to −100% that essentially switch off an
entire current), and there is some suggestion that a level of variability such as ±30% is
more appropriate for cardiac ion channel conductances [41, 19, 9]. We therefore seek to
answer the question of whether 30% variability sufficiently explains the variation in the
dataset we calibrated to.
In order to select the most relevant portion of the parameter space, we take parameter
values ±30% around the values selected for the modified CRN models in the previous
section. Applying our SMC sampling algorithm and subsequent refinement, we obtained
254 models calibrated to the SR dataset, and 215 models calibrated to the cAF dataset,
the minimum allowable number of models in both cases. Neither of these POMs succeeded
in fully capturing the variability in the dataset, resulting in divergence measures that
compare unfavourably to those obtained using the full ±100% variation in cell properties
(Table 4). Examination of the marginal distributions of the biomarkers for the SR ±30%
POM reveals that it does successfully capture the general distributions of the data, but
fails to show the same extent of variance (Figure 9). Similar results are also seen for the
cAF ±30% POM (Figure S7).
Population of Models SR data cAF data
ρ ρˆ ρ ρˆ
±100% parameter space ρˆ 1.47 0.49 1.28 0.57
±30% parameter space ρˆ 1.79 1.01 1.77 1.19
Table 4: Variability of 30% in ion channel conductances fails to fully explain the
variable data. Comparison of the ability of different POMS to capture the between-
subject variability in two clinical datasets, when the extent of underlying variability in
ion channel conductance is decreased. The larger ρ and ρˆ values seen for the ±30% POMs
indicate a more significant divergence between POM and data, resulting from the inability
to find models in this smaller parameter space that produce all of the combinations of
biomarker values in the dataset.
Furthermore, the secondary mode in the distribution of SR APD50 values is com-
pletely unrepresented by the POM constructed with reduced variability. This peak most
likely corresponds to cells that repolarise more than 50% during the phase of immediate
repolarisation, driven primarily by the rapidly activated outward currents Ito and IKur.
This results in a cluster of very small APD50 values that are separate from the majority of
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Figure 9: Variation of ±30% in current densities underestimates biomarker
variance in the SR dataset. Marginal distributions of the biomarkers in the SR
dataset (black) and distribution-calibrated POM using ±30% variance in ion channel
conductances (blue). A reduced search space is still able to recover the general distri-
butions of all biomarkers except for dV
dt max
, but the full extent of variation in the APD
biomarkers and V20 is not present in the calibrated POM. Notably, the very low APD50
values recorded for some patients are completely unrepresented in the POM (arrow).
cells, which only reach 50% repolarisation after the plateau phase. General underestima-
tion of biomarker variability in the POM could potentially be explained by measurement
error associated with the biomarker data, but the inability to produce models that popu-
late this peak implies that additional variance in cell properties, at least those relevant to
Ito and/or IKur, are required to produce models that exhibit sufficient early repolarisa-
tion. Coupled with the general underestimation of biomarker variance in the POM, these
results certainly imply that additional variability in ion channel conductances beyond
±30% underlies the variability in biomarkers that is seen in these datasets.
Discussion
Population-based modelling is a powerful technique for allowing deterministic mathemat-
ical models to explore and characterise the variability inherent in complex systems [1].
This includes the use of multiple regression techniques performed on synthetic popula-
tions [42, 43, 44], and when data is explicitly available, calibrated POMs [9]. Previously,
calibration of POMs has been performed by ensuring that all relevant model outputs
fall within the ranges of the data [7, 19, 17]. While this is a perfectly reasonable ap-
proach, especially when a low number of experimental samples is available, it does ignore
other information inherent in the data and does not strictly guarantee that the models
selected will produce outputs that correspond to those seen in the data. Our presented
calibration technique estimates the underlying distribution of outputs represented by the
data and calibrates to this distribution using a combination of SMC [16] and a simulated
annealing-type algorithm.
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We have demonstrated the efficacy of our technique on a pair of datasets from car-
diac electrophysiology, a field that has seen a great deal of POMs research following
Prinz, Bucher and Marder’s [5] and Marder and Taylor’s [6] pioneering studies in neuro-
science. The data used was comprised of biomarker values collected for atrial myocytes
from hearts exhibiting healthy SR or the cAF pathology [19], offering two sets of data
to test the calibration technique and the opportunity to compare the models selected to
represent healthy and afflicted hearts. Use of SMC to sample according to the distribu-
tion of data was found to improve the correspondence between POMs and experimental
observations over LHS matched to ranges, but the approximate nature of the technique
left room for further improvement. A subsequent refinement technique to select optimal
subpopulations of the SMC-constructed POMs was able to fully recover the variability in
the dataset, except where the underlying model was incapable of producing the outputs
that were experimentally observed.
Our approach generates models that predict very well the morphologies of different
types of APs associated with SR or cAF. The cAF models also demonstrate a more
realistic response to antiarrhythmic treatment (AP prolongation in response to IKr block
[37, 45]), as compared to the original CRN model. These benefits remained even when
the population of models was averaged to produce a single model, demonstrating the
efficacy of the technique for the more general problem of selecting parameter values in
response to variable data. Taking into account the variability in data in this fashion,
as opposed to simply averaging it and fitting parameters to the result, is of particular
importance when a system (and its associated mathematical model) is complex, such as
in our example of cardiac electrophysiology where the ability of currents to compensate
for one another allows for highly similar APs to be produced by very different balances
of constituent currents [7, 46].
Furthermore, calibration that takes more of the features of data into account may be
able to resolve more subtle differences between datasets, making it a powerful approach
for identifying the potential causative factors that produce these differences. In our case,
calibrating POMs to the distribution in the SR and cAF datasets was able to select POMs
with very distinct parameter values, and these differences in parameter values were seen to
be indicative of the known changes in atrial myocyte behaviour associated with the cAF
pathology [26, 27]. Interestingly, differences in the action of the sarcoplasmic reticulum
were also identified, despite the uptake and release of Ca2+ internally not contributing
directly to the AP [23]. We suspect that the contribution of the internal calcium dynamics
to the current through the Na+/Ca2+ exchanger allows them to be partially identified,
even when calibrating only to AP biomarkers, but this point requires further investigation
beyond the scope of this paper.
In this case, following the available data, we have used the well-studied cAF pathology
to demonstrate our density-based calibration technique’s ability to detect the differences
in parameter values that underlie different datasets. However, appropriately-calibrated
POMs could also be used to potentially identify differences in behaviour (codified by
parameter values) that explain pathological conditions that are not as well understood.
This same thought also extends to improved identification of any differences that underlie
artificial stratifications of a dataset, for example differences in physiology that correspond
to factors such as gender or age [47, 48].
When constructing POMs without experimental evidence for the extent of variability
in parameters, the choice of parameter space to sample is open. Our primary study used
a large space of parameter values (±100%) to give the model the best opportunity to
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simultaneously fit the two different sets of data and hence demonstrate our technique.
However, we also considered the effects of choosing a smaller parameter space (±30%, [41,
15, 19]), attaining results that imply that ±30% variance in primary current conductances
is insufficient to explain the experimental data, and thus that further variation in these
cell properties or others is expected. This sort of exploration into appropriate levels
of variability is particularly important in fields such as cardiac electrophysiology, where
the variable cell properties are difficult to directly measure and the extent of variability
is not well established [49]. Such analysis requires the ability to calibrate POMs to
distributions, so that the comparisons between parameter spaces of different sizes are
unaffected by model bias.
There are several circumstances under which our calibration process might fail or be
considered inappropriate. Firstly, calibrating to distributions requires sufficient data in
the dataset to form a reasonable approximation to the underlying distribution. When the
sample size is insufficient compared to the variance to suggest a specific distribution with
any real confidence, obviously distributional calibration is inappropriate and calibration
based on range statistics is very reasonable. However, even in these cases a benefit can
potentially be gained by enforcing that data is spread evenly across its range, although
we have not investigated this in this paper. Secondly, when the model itself is incapable
of producing outputs that correspond to some experimental data, no calibration process
will allow it to capture these portions of the data. In this scenario, the model itself must
be examined, or the experimental protocols reconsidered. This does however demonstrate
the usefulness in considering the distribution of the data and how well constructed POMs
fit to it using measures such as ρ, in that it suggests when models (or possibly experi-
ments) might need to be reconsidered. Indeed the varying ability of different models to
successfully produce POMs calibrated to a given dataset also serves as a means of com-
paring and benchmarking them. Lastly, the reliance upon a transformed target density
in the SMC algorithm might potentially cause it to select models that do not accurately
capture the distribution of outputs in the data, even though on our test problem the
method has been seen to perform very well. In the worst case, ‘naive’ POMs composed
of large numbers of models can be constructed by sampling the search space uniformly
(such as through LHS) and then refined by our simulated annealing process to select the
subpopulation of these that best matches the data.
In conclusion, our presented calibration technique allows datasets to be thoroughly
mined in order to produce informative and predictive POMs that capture the variability
between individual members of a population. The benefits of successfully accounting
for this variability are well established [1], including the selection of parameter values in
response to variable data, uncovering differences in underlying behaviour that characterise
different datasets (or stratifications within a single dataset), identification of factors that
may predict the differential response to drug treatments, and better informed comparisons
between different models for the phenomena in question. We have demonstrated how
POMs calibrated to the distributions in data using our approach can successfully perform
these functions using a real dataset in atrial electrophysiology. The technique is best
suited to datasets that are large enough to clearly suggest an underlying distribution
of the quantities being observed, but calibration to smaller datasets could potentially
be achieved by fitting to uninformed distributions that simply ensure that the resultant
outputs of constructed POMs are sufficiently spread across the range of potential values.
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Materials and Methods
Experimental Dataset
The clinical data used in this work was that presented by Sanchez et al. [19], namely
biomarker values measured from recorded action potentials for 469 cells taken from
the right atrial appendages of 363 patients. These biomarker readings were split into
two groups, patients exhibiting standard sinus rhythm (SR) and patients exhibiting
chronic atrial fibrillation (cAF). The biomarker values used to quantify the action po-
tentials were the action potential durations compuated at 20, 50 and 90% repolarisation
(APD20, APD50, APD90), the action potential amplitude (APA), resting membrane po-
tential (RMP), the potential at 20% of APD90 (V20) and the maximum upstroke velocity
(dV/dtmax). More information regarding the experimental conditions under which the
data was collected is available in [19].
The data demonstrates statistically significant differences between biomarker values
for SR and cAF cells, with p < 0.001 for all biomarkers except dV/dtmax [19]. The
relatively large size of the dataset allows for the specific distributions of each biomarker,
and their dependencies on each other, to be meaningfully explored.
We also note that this dataset was ideal for the development of our new POM cal-
ibration technique based on capturing the distributional features of a dataset in that
biomarker readings were collected from over 200 myocytes from patients in both SR and
cAF and therefore sufficient data is available to make distributional calibration both
meaningful and appropriate.
Atrial AP Model
This work used the Courtemanche–Ramirez–Nattel (CRN) model for atrial action poten-
tials [23], following preliminary studies that suggested it was most able to capture the
biomarker values seen in the Sanchez et al. dataset. A separate benchmarking study
also suggested that this model, despite being one of the first developed for human atria,
predicted APDs very well for data from both SR and cAF patients [50]. The CRN model
uses twenty-one coupled ordinary differential equations to simulate amongst other things
the activation and inactivation of nine different sarcolemmal ion channels, as well as the
actions of the sarcoplasmic Ca2+ pump, Na+/K+ pump and the Na+/Ca2+ exchanger,
which all contribute to the flow of ions in or out of an atrial cell and thus to the changes
in membrane potential that create the action potential. Ion channels are modelled using
a Hodgkin-Huxley [51] type formulation, with combinations of gating variables repre-
senting the presence/absence of activators/inhibitors that determine channel availability.
Ca2+ uptake into the network sarcoplasmic reticulum, release from the junctional sar-
coplasmic reticulum and the transfer (active or leak) between these two compartments
are also represented. For full details of the model, including the specific forms of each of
its differential equations see [23].
We simulated the CRN model using MATLAB’s ode15s routine, with a maximum step
size of ∆t = 1ms. Biomarkers were measured from output V (t) curves, after discarding
any action potentials that failed to excite above −30mV, failed to repolarise to a value
of RMP+0.1APA, or exhibited spontaneous depolarisations (judged as subsequent peaks
after repolarisation to the aforementioned value). Following Sanchez et al., the model
was paced until it reached steady state (≤1% change in all state variables) and then
90 more times, using a stimulus of 2ms of −2210 pA, approximately twice the diastolic
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threshold for the base model. Temperature and external ion concentrations were adjusted
to match the experimental conditions (T = 309.65K, [Na+]o = 149.42mM, [K
+]o =
4.5mM, [Ca2+]o = 4.5mM). No other parameters were modified from their values in the
originally published version of the model.
The process of simulating the CRN model (with input parameters θ) and the subse-
quent calculation of biomarkers from the resulting action potential will be denoted M,
and the output biomarkers denoted y, such that
y =M(θ). (1)
Populations of CRN Models
Populations of models were constructed here by varying a set of inputs to the CRN model,
namely the current densities of the fast Na+ current, the five outward K+ currents (tran-
sit outward, ultrarapid delayed rectifier, rapid and slow delayed rectifiers and the inward
rectifier), the L-type inward Ca2+ current, the Na+/K+ pump and Na+/Ca2+ exchanger,
and the maximal rates of uptake and release of Ca2+ inside the cell by the sarcoplasmic
reticulum. Following the notation used in the original CRN paper, the set of inputs
is here denoted θ = (gNa, gto, gKur, gKr, gKs, gK1, gCaL, INaK(max), INaCa(max), Iup(max), krel),
with g denoting the maximal conductances of the different currents, I(max) denoting the
maximal actions of pumps and exchangers and krel being the conductance of the ryan-
odine receptors that release Ca2+ from the sarcoplasmic reticulum. These were the same
currents varied by Muszkiewicz et al. in their construction of POMs for human atria
[11]. Sanchez et al.’s study [19] varied only the six currents they identified as having
a significant impact on biomarker values [52], and thus did not include gNa, gKr, gKs,
Iup(max) or krel.
Following Sanchez et al., POMs were constructed using a search space of ±100% from
the base parameter values for the CRN model. However, whereas their work selected
trial points using the sampling method underlying Fourier amplitude sensitivity testing
[53] and then rejected those that did not produce APs with biomarkers falling within
experimentally observed ranges, we used the method described subsequently to produce
POMs that not only corresponded to the spread of the experimental data, but also
reproduced its distributional features.
Biomarker Joint Distribution Estimation
Distributional calibration first requires estimating the distribution represented by the
data, p(y). This was achieved here by multivariate kernel density estimation, which
creates a smooth distribution by summing over a series of multivariate Gaussians centred
at each of the N individual datapoints,
p(y) ≈ 1
det(H)−1/2N(2pi)−Nb/2
N∑
i=1
e−1/2(y−y˜i)
TH−1(y−y˜i). (2)
Here Nb is the number of biomarkers (seven in this case), y˜i are the individual points of
biomarker data and H is the bandwidth matrix, a parameter of the density estimator that
controls the extent and direction of smoothing. When the distribution to be estimated is
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normal with unit variance, the optimal bandwidth can be shown [54] to be
hopt =
(
4
N(Nb + 2)
) 2
Nb+4
, (3)
which motivates a choice of bandwidth matrix
Hij = hopt σ
2
i if i = j (4)
= 0 if i 6= j
Thus the extent of smoothing is weighted in each dimension in terms of the variance in
that biomarker observed in the dataset, but correlations between biomarkers are ignored
in the choice of H. Note that the estimated density still attempts to account for depen-
dencies between biomarkers. The choice to use a diagonal bandwidth matrix tends to be
sufficient in practice [55].
Another alternative to multivariate kernel density estimation is to approximate p(y)
by combining the marginal distributions of each biomarker with a Gaussian copula to
approximate their interdependencies. However, for the atrial datasets we use to demon-
strate our calibration technique, this approach was found to be less effective and so is
not discussed further here.
APD20 readings in the SR dataset were predominantly clustered at low values, but
with a considerable range. To improve the performance of the kernel density estimation
(recalling the bandwidth was selected as optimal for normally distributed data), the
APD20 values were first logarithmically transformed to make their distribution more
regular before use in equation (2).
SMC for POM Calibration to Distributions
Constructing a population of θ values that exhibits the estimated distribution p(y) is
not trivial, given the complex relationship between the two encoded by equation (1). We
define g(θ) to be a probability density over the space θ, and the population distribution
of the model output M(θ) when θ is drawn according to this distribution we denote
h(y|g(θ)), with the vertical bar | denoting conditioning. That is, h(y|g(θ)) is the density
of M(θ) when θ ∼ g(θ):
h(y|g(θ)) = lim
∆y→0
1∏Nb
k=1 ∆bk
∫
M(θ)∈(y,y+∆y)
g(θ)dθ,
where ∆y = (∆b1 , . . . ,∆bNb ). Our problem is thus recast as finding the distribution g(θ)
that produces a h(y|g(θ)) that is as close as possible to p(y). Models sampled according
to this optimal g(θ) will then exhibit outputs that reproduce the estimated distribution
of outputs in the data.
If the “closeness” of h(y|g(θ)) and p(y) is measured in terms of the Kullback-Leibler
divergence between the two distributions, the problem is an optimisation problem
g∗(θ) = arg min
g(θ)
∫
y
ln
(
h(y|g(θ))
p(y)
)
h(y|g(θ))dy. (5)
The standard method for solving this type of problem is to follow a variational Bayes
(VB) type of approach. VB is commonly used to produce parameteric approximations of
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posterior distributions in Bayesian statistics [56, chap. 11]. Applying VB to our problem
would involve specifying some parametric distribution for g(θ) ≡ g(θ|φ), where φ are the
parameters of the distribution. For example, if a multivariate normal distribution was
adopted for g, φ would consist of a mean vector and covariance matrix. Using VB, the
problem (5) then reduces to finding the optimal parameters φ∗ = arg minφ f(φ), with the
integral in equation (5) approximated by Monte Carlo integration taking K independent
draws from g(θ|φ),∫
y
ln
(
h(y|g(θ|φ))
p(y)
)
h(y|g(θ|φ))dy ≈ 1
K
K∑
k=1
ln
(
hˆ(yk|g(θ|φ))
p(yk)
)
= f(φ),
where yk =M(θk) and θk ∼ g(θ|φ) for k = 1, . . . , K. For a particular φ, an estimate of
h(y|g(θ|φ)), which we denote as hˆ(yk|g(θ|φ)), could be obtained using a kernel density
estimate as in equation (2) based on the set of simulated biomarker values {yk}Kk=1. There
are several reasons why we did not adopt this approach: firstly it requires us to specify
a parametric form for g(θ), secondly evaluating f(φ) is very expensive as it involves
solving the model K times and thirdly φ will be high-dimensional, leading to a difficult
optimisation problem.
Instead, we used an approach that is more pragmatic and effective in this application.
First, we determined a collection of θ values (or models) that produced biomarker values y
that have relatively high density with respect to the data density p(y). Then, we removed
models from this collection in an iterative fashion so that the distribution of corresponding
biomarker values that remained was even closer to p(y) (see Section “Further POMs
Refinement”).
For the first step we used sequential Monte Carlo (SMC, [57]), following the use of the
technique to construct POMs calibrated to ranges in data [16]. This technique begins with
a set of N particles and traverses them through a sequence of probability distributions
by iteratively applying importance sampling, resampling and move steps. We achieve
this behaviour by sampling from the sequence of distributions h(θ) ∝ p(M(θ))γ , with
γ ∈ [0, 1]. It can immediately be seen that γ = 0 corresponds to the uniform distribution,
which is very easy to sample if we specify some lower and upper limits for each component
of θ, and that γ = 1 corresponds to a distribution proportional to p(M(θ)), which
is potentially difficult to sample. Successively incrementing γ after each resample and
move step until γ reaches one allows for the complexity of the sampling problem to
be introduced gradually. An important aspect of SMC is that it does not require the
distributions in the sequence to be properly normalised. The full SMC algorithm is laid
out in the supplementary material.
The algorithm requires the use of traditional Markov chain Monte Carlo (MCMC,
[58]) steps in order to find unique locations for particles after each resampling step,
and the particles must still represent samples from the current target distribution. This
is achieved using the Metropolis-Hastings algorithm, which, in our set-up, accepted or
rejected any proposed particle moves according to
Pr(accept) = min
(
1,
[p(M(θnew))]γJ (θold|θnew)
[p(M(θold))]γJ (θnew|θold)
)
. (6)
Here J is the jumping distribution that generates proposed moves of particles, and in our
case does not depend on the previous particle location (that is, J (θnew|θold) = J (θnew)).
The jumping distribution used is a Gaussian mixture model built for a regularised version
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of the current of locations of all particles after a resampling step (see SMC Algorithm in
the supplementary material). The number of MCMC steps performed after each resam-
pling step is chosen adaptively [59].
The output of the SMC algorithm is a collection of samples {θi}Ni=1 from a distribution
proportional to p(M(θ)). We note that the corresponding collection of output values
{yi}Ni=1, where yi = M(θi), is not a sample from the distribution of interest, p(y).
The reason for this is that we have not accounted for the nonlinear transformation,
y = M(θ) to correctly convert the target distribution over the output space to the
corresponding target distribution over the parameter space. However, given the fact that
the transformation y =M(θ) is not analytic and not a one to one function, we suggest
that it is not tractable to properly account for it and indeed it may not even be possible
to find a distribution over θ that leads to a distribution of biomarker values consistent
with p(y).
Nonetheless, we found that this approach led to a collection of parameter values
that generated biomarker values with relatively high density under p(y). We used this
collection as the starting point for our subsequent refinement process.
As an alternative to SMC, an MCMC approach could also be used directly to produce
samples from a distribution proportional to p(M(θ)), using the same density (2) and
acceptance algorithm (6) with γ = 1. Indeed we used a modern state-of-the-art MCMC
sampler, DiffeRential Evolutionary Adaptive Metropolis (DREAM) [60] to verify our
SMC algorithm and found that the two produced comparable results in terms of the
distribution of the values of θ produced. The primary benefit of the SMC algorithm,
when it came to the construction of our initial POM, was that the output of the algorithm
is a set of unique samples from the distribution almost the same size as the number of
particles, N , which is specified by the user. In contrast, MCMC approaches must be run
an indefinite amount of time until the chain has been judged to have converged, producing
a long chain of samples of initially unknown length. Moreover, these chains contain many
repeated samples, and filtering out these repeats will also destroy the desired distribution.
Further POMs Refinement
The approximate nature of the SMC calibration process encouraged further refinement
of the constructed POMs in order to fully capture the statistical distributions seen in
the data. This was achieved by selecting a subset of the population such that the new
smaller set of models better exhibited the biomarker distributions seen in the data. In
order to do this, first a quantitative measure of how well a POM captured the distributions
observed in the data was constructed. We used the Jensen-Shannon distance (JSD), a
symmetric and finite version of the Kullback-Leibler divergence that remains a measure
of the ‘distance’ between two probability distributions. Labelling the two distributions
p(y) and q(y), the Jensen-Shannon distance is given by
JSD =
[
1
2
∫
y
p(y) ln
(
p(y)
1
2
p(y) + 1
2
q(y)
)
dy +
1
2
∫
y
q(y) ln
(
y)
1
2
p(y) + 1
2
q(y)
)
dy
]1/2
, (7)
with the square root used to make the divergence measure a metric [61].
When the data is high-dimensional (say N ≥ 5), the ‘full’ JSD between the multi-
variate joint distributions of the observations in the dataset and those generated by a
given POM is difficult to calculate accurately. Therefore, we instead used the distances
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between the marginal distributions for each of the biomarkers, JSDi, along with the
distances between the bivariate distributions between all possible pairs of observation
variables, JSDij to create a matrix, the norm of which serves as an approximate measure
of fit, namely
ρ = ||P||2 , (8)
Pij =
{
JSDi i = j
JSDij i 6= j (i, j = 1, ..., NB).
The measure ρ takes into account how well the individual distributions of each observed
variable are represented by a POM, along with some measure of how well it captures
the dependency between these variables. We note that this is not necessarily the best
measure of fit, but uses more easily calculated divergences to produce a single value,
allowing the use of the technique described below. JSD values used in the calculation of
ρ, as integrals, were approximated using standard Riemann integration.
Our refinement process seeks to minimise ρ, using a supplied POM. In this work we
use POMs selected using SMC to improve fit with the data, though we note that POMs
constructed using typical Monte Carlo sampling techniques (such as LHS and calibrated to
the ranges of the data) could also be used as starting points for our refinement procedure.
Minimisation is achieved by trialling removal of individual models from the population
(or re-introduction of removed models) and then accepting or rejecting them according
to the Metropolis probability,
Pr(accept) = e−∆ρ/T . (9)
Here ∆ρ is the change in the overall divergence measure (8) associated with the trialled
removal/re-introduction and T is a parameter of the process that controls the likelihood
of accepting unfavourable trial updates. This approach is very similar to the approach of
simulated annealing [62], although we use a fixed value of T = 0.1 instead of gradually
decreasing it. Every 1000 trial steps, we judge if the choice of subpopulation is wandering
too far away from the optimum by checking if ρ is more than 1% larger than the current
best ρ value found, and if so, restart the process back to the configuration corresponding
to the best ρ value.
The only additional condition we use is that the size of the subpopulatoin of models
cannot fall below the number of datapoints, ensuring that the resulting population will
not become small enough to lose meaning. If a larger population of models is desired, ρ
(representing the ‘energy’ of the system that is minimised over the course of the annealing
process) can be replaced by a new expression in equation (9) that penalises both higher
values of ρ and small numbers of models in the population.
We saw (see Results) that the data for one biomarker, namely the maximum upstroke
velocity, took values not predicted by the CRN model in the search space, and strong
correlations exhibited by the model were not seen in the data. This made it appealing to
de-emphasise the contributions of this biomarker to the POM refinement process. This
was achieved by creating a second divergence measure, ρˆ, that is the 2-norm of a mod-
ified version of the performance matrix P with the row and column corresponding to
the maximum upstroke velocity overwritten with zeroes, except for the diagonal element.
Minimising ρˆ instead allowed the distributions of the other biomarkers to be better fit
by the refinement process, at the cost of producing POMs that did not strongly reflect
the distribution of maximum upstroke velocities in the data. Given that we expected the
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maximum upstroke velocity to be the biomarker most subject to experimental measure-
ment error in the data, we consider this a reasonable decision.
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Figure S1: Calibration to biomarker distributions, as opposed to their ranges,
significantly reduces model bias for the cAF dataset. Marginal distributions of
the biomarkers in the cAF dataset (black) and POMs calibrated to biomarker distribu-
tions using the SMC algorithm (blue) or calibrated to biomarker ranges using LHS (red).
Calibration to biomarker distributions, as opposed to their ranges, significantly reduces
model bias and produces a much more representative POM. This is demonstrated by the
marginal distributions of POMs constructed with LHS matched to ranges (red) and SMC
calibrated to the biomarker distribution (blue) in comparison with the marginal distri-
butions of the biomarkers in the cAF dataset (black). SMC demonstrates a significant
improvement in capturing the distributions of almost all biomarkers.
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Figure S2: Bivariate distributions of biomarker pairs are well captured by
an SMC-constructed POM for the cAF dataset. Pairwise scatterplots of each
unique pair of biomarkers in the SR dataset (white) and the POMs constructed using
SMC matched to distributions (blue) and LHS matched to ranges (red). The SMC-
generated POM demonstrates better localisation to the dense regions in the data, but
clearly requires further calibration. The same very strong correlation between APA and
dV
dt max
seen for models selected to match the SR dataset is also seen here.
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Figure S3: Variability in the cAF dataset is captured by a population of CRN
models with varying current densities. Marginal distributions of the biomarkers in
the cAF dataset (black) and the POMs constructed using SMC followed by simulated
annealing to minimise ρ (red) or ρˆ (blue). Matching of the univariate biomarker distribu-
tions is slightly less well achieved than in the case of the SR datsaet, but the calibration
process is clearly very successful and the trends in the data captured by the constructed
POM.
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Figure S4: Simulated annealing successfully selects models according to data
density in the biomarker space in the cAF dataset. Pairwise scatterplots of
each unique pair of biomarkers in the cAF dataset (white) and the models from the
SMC-generated POM that are accepted (light blue) or rejected (grey) in the process of
minimising ρˆ. Only the spread of, and correlations with, dV
dt max
are not captured very
well by the final POM.
Figure S5: Calibration to ranges fails to capture the morphological differences
between SR and cAF atrial action potentials. Atrial action potentials produced
by simulation of the populations of CRN models calibrated to the ranges of biomarker
data for patients exhibiting sinus rhythm (blue) and chronic atrial fibrillation (red). Also
displayed are the average of all traces for the sinus rhythm (solid) and atrial fibrillation
(dashed) populations. Differences in AP morphology are far less pronounced than those
observed using calibration to distributions, and a small number of simulated APs appear
unphysical.
36
Figure S6: The distributions of parameter values selected for the SR and cAF
POMs are distinct, but regular. Pairwise scatterplots of the parameter values se-
lected for POMs calibrated to the SR (blue) and cAF (red) datasets, expressed in terms of
the proportion of the base values for parameters in the CRN model. Clear differences in
the two distributions can be observed, but neither POM exhibits obvious patterns of cor-
relation in any pair of parameters, nor is there evidence of bimodality. These properties
are important when reducing a POM back to a single representative model.
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Figure S7: Variation of ±30% in current densities underestimates biomarker
variance in the cAF dataset. Marginal distributions of the biomarkers in the cAF
dataset (black) and distribution-calibrated POM using ±30% variance in ion channel
conductances (red). A reduced search space is still able to recover the general distributions
of all biomarkers except for dV
dt max
and V20, with the extent of variation in APD50 also
significantly underestimated.
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Biomarker Range Mean Std. Dev. JSD
APD90 (ms) 148−351 (141−349) 216 (216) 33 (35) 0.032
APD50 (ms) 33−168 (36−182) 101 (102) 28 (28) 0.040
APD20 (ms) 2−114 (4−82) 29 (30) 20 (18) 0.075
APA (mV) 81−119 (74−133) 102 (102) 7 (8) 0.075
RMP (mV) -87−-68 (-90−-66) -77 (-77) 3 (4) 0.073
V20 (mV) -29−21 (-33−21) -4 (-4) 10 (11) 0.049
dV
dt max
(V/s) 101−301 (40 −414) 189 (232) 34 (70) 0.361
Table S1: Summary statistics for the cAF dataset are well recovered by the
calibrated POM. Summary statistics for the POM calibrated to the distributions in
biomarkers exhibited by atrial cells from hearts exhibiting cAF, as compared to the
summary statistics for the experimental data itself (given in parentheses). Deviation
in the marginal distributions of each biomarker are specified in terms of the Jensen-
Shannon distance (JSD), calculated using equation (7). As with the case of the SR data,
the statistical distribution is well captured apart from the maximum upstroke velocity.
Values shown are for the POM obtained by minimising ρˆ.
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Algorithm 1 SMC algorithm for construction of a POM fitted to an underlying distri-
bution of biomarkers, p(y).
. Initialise particles
Set i = 0
while i ≤ Nparts do
Select a random θ from the search space and calculate y =M(θ)
if action potential not rejected (see Materials and Methods) then
Set i = i+ 1
Store particle location in parameter space, θi and biomarkers, yi
Store particle likelihood, Li = p(yi)
end if
end while
. Gradually increment γ until the true distribution is sampled
Set γ = 0
while γ < 1 do
. Check if current particles sufficiently reproduce the desired distribution
if ESS(γ, 1) ≥ Nparts/2 then
Set γ = 1
else
Find γ′ such that ESS(γ, γ′) = Nparts/2
end if
. Resample particles according to the new distribution
Calculate normalised weights for particles, wi = Li (γ′−γ)/
∑Nparts
j=1 Lj (γ′−γ)
Resample particle locations θ ∼ Multinomial(w)
Update γ → γ′
. Attempt to remove particle duplications via MCMC move steps
Construct the jumping distribution, J (θ) = BuildJumpDist(θ)
Update particle locations, [θ,y, acc] = MCMCMove(θ,y)
Determine optimal number of MCMC iterations, R = ceil
(
ln 0.05
ln(1−acc)
)
for i = 1 to min(R− 1, 29) do
[θ,y,∼] = MCMCMove(θ,y,J (θ))
end for
end while
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Algorithm 2 Ancillary functions used by the SMC algorithm
function ESS(γ, γ′)
Calculate particle weights, wi = Li (γ′−γ)/
∑Nparts
j=1 L(γ′−γ)
Return estimated sample size, ESS = 1/
∑Nparts
j=1 wj
2
end function
function J (θ) = BuildJumpDist(θ)
. Regularise the marginal distributions of θ
Scale particle locations to [0, 1], φi =
θi−θmin
θmax−θmin
Fit a beta distribution to the values of φ.
Use this to find an optimal mixture of two beta distributions, f(φ)
Use the cdf of the beta mixture, ui = F (φi) to obtain approximately uniformly
distributed particles
Transform these into normally distributed particles, z = norminv(u)
. Jumping dist. is Gaussian mixture model on regularised distributions
Fit a mixture of three Gaussians to particle z’s using MATLAB’s fitgmdist
Store the Gaussian mixture model, J (z)
Calculate and store J (z) for all particles
end function
function [θ,y] =MCMCMove(θ,y,J (θ))
for i = 1 to Nparts do
Propose z′i ∼ J (z)
Transform z′i back to θ
′
i
Evaluate the model, y′i =M(θ′i)
. Accept or reject according to Metropolis-Hastings algorithm
Generate a uniform random number r ∼ [0, 1]
if r < min
(
1,
[p(y′i)]
γJ (θi)
[p(yi)]γJ (θ′i)
)
then
Update θi → θ′i, yi → y′i
end if
end for
end function
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